JNJ-78278343
Sponsors
Janssen Cilag International, Janssen Research & Development, LLC
Conditions
AdenocarcinomaAdvanced Prostate CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Phase 1
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Active, not recruitingNCT04644770
Start: 2020-11-12End: 2027-01-15Updated: 2026-03-13
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Active, not recruitingNCT04898634
Start: 2021-07-13End: 2027-02-10Updated: 2026-02-13
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
RecruitingNCT06095089
Start: 2023-11-01End: 2028-06-28Target: 250Updated: 2026-02-17
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RecruitingNCT07082920
Start: 2025-07-07End: 2027-03-01Target: 140Updated: 2026-03-13
Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer
RecruitingCTIS2025-520927-26-00
Start: 2025-11-24Target: 247Updated: 2026-01-27
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
Not yet recruitingCTIS2025-522713-29-00
Target: 63Updated: 2026-03-10